Kymera's oral candidate KT-621 for eczema receives Fast Track designation.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy KYMR?
Source: SeekingAlpha
FDA Fast Track Designation: The US FDA has granted Fast Track designation to KT-621, an oral STAT6 degrader for atopic dermatitis developed by Kymera Therapeutics.
Positive Phase 1 Data: The designation follows positive phase 1 data released on December 8, which significantly boosted Kymera's stock prices.
Current Phase of Development: KT-621 is currently in phase 2 of its clinical trials.
Recent Financial Moves: Kymera Therapeutics has also announced a $602 million public offering priced at $86.00 per share, along with a proposed $500 million public offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KYMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KYMR
Wall Street analysts forecast KYMR stock price to rise
22 Analyst Rating
21 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.160
Low
90.00
Averages
116.30
High
138.00
Current: 78.160
Low
90.00
Averages
116.30
High
138.00
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nextech Reduces Stake in Kymera Therapeutics: Analysis
- Transaction Overview: Nextech Invest, Ltd. reduced its stake in Kymera Therapeutics by selling 62,013 shares, valued at approximately $4.19 million, reflecting a cautious management strategy regarding its investment in the company.
- Position Value Change: Despite the sale, the value of Nextech's Kymera position increased by $2.41 million at quarter-end, indicating a positive impact from stock price appreciation on the overall portfolio.
- Asset Allocation Analysis: Kymera now represents 2.1% of Nextech's assets under management, positioning it as a satellite investment compared to the fund's concentrated holdings, highlighting its relatively lower significance in the overall portfolio.
- Market Outlook: Kymera Therapeutics focuses on targeted protein degradation therapies in immunology and oncology; although Nextech trimmed its position, the continued holding indicates confidence in the company's clinical pipeline, suggesting investors should watch for future catalysts.
See More
Nextech Reduces Stake in Kymera Therapeutics
- Transaction Overview: Nextech Invest disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Kymera Therapeutics by 62,013 shares, with an estimated transaction value of $4.19 million, reflecting the company's agile response to market fluctuations.
- Position Value Change: Despite the reduction, the quarter-end value of Kymera's position increased by $2.41 million, indicating a positive impact from stock price appreciation and suggesting Nextech's long-term confidence in the stock.
- Holding Proportion Adjustment: Following this transaction, Nextech's stake in Kymera now represents 2.1% of its assets under management, moving it outside the top five holdings, which highlights the fund's concentrated investment strategy and risk management approach.
- Market Performance Analysis: As of February 17, 2026, Kymera's stock price stood at $84.84, reflecting a 128.5% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its strong position in the biotechnology sector.
See More
Analysis of KYMR Options Trading Dynamics
- Options Selling Risks: Selling puts on KYMR does not provide investors with the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, and unless KYMR's shares decline by 31.3%, the only benefit is a 15.1% annualized return from the premium.
- Cost Basis Analysis: If the contract is exercised, the seller's cost basis would be $52.80 per share after deducting the $7.20 option fee, indicating a mismatch between risk and reward when selling puts at the current market price.
- Volatility Assessment: With a trailing twelve-month volatility of 74% for KYMR, this metric, combined with fundamental analysis, can assist investors in determining whether selling the December put at a $60 strike price is worthwhile, especially given the current stock price of $87.93.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Company Announcement: Kymera Therapeutics plans to sell 200,000 shares of its common stock on March 2.
Market Value: The total market value of the shares being sold is approximately $18.27 million.
See More
Piper Sandler Raises Kymera Price Target to $140 on Strong Clinical Data
- Analyst Rating Upgrade: Piper Sandler raised Kymera Therapeutics' price target from $125 to $140, reflecting strong confidence in its oral protein degraders, which is expected to drive the company's stock price higher.
- Clinical Data Support: Early clinical data indicates that Kymera's STAT6 degrader program can achieve biologic-like pathway suppression in a convenient and scalable oral formulation, further solidifying its position as a category leader.
- Market Competitive Advantage: Piper believes that Kymera's first-mover advantage in immunology degraders and oral differentiation compared to biologics provide an attractive risk-reward profile in the current market environment.
- Optimistic Investment Outlook: With expanding clinical evidence, Piper Sandler maintains an optimistic view on Kymera's future performance, believing it has significant growth potential in the emerging oral atopic dermatitis market.
See More
Kymera Therapeutics Highlights Q4 2025 Earnings Call
- Significant R&D Progress: Kymera Therapeutics achieved a breakout year in 2025, with CEO Mainolfi highlighting outstanding results from KT-621's clinical trials, expecting to share data by mid-2027, indicating substantial potential in the atopic dermatitis market that could drive market share growth.
- Strong Financial Position: The company ended the year with a cash balance of $1.6 billion, with CFO Jacobs reporting collaboration revenue of $2.9 million in Q4 and R&D expenses of $83.8 million, showcasing a robust financial foundation to support future R&D plans and market expansion.
- New Partnerships Established: Kymera formed a new partnership with Gilead focusing on the CDK2 molecular glue program, while ongoing collaboration with Sanofi continues, which will provide additional revenue streams and technical support, enhancing competitive positioning in the market.
- Strategic Leadership Change: The appointment of Neil Graham as the new Chief Development Officer, who previously led the dupilumab project at Regeneron, is expected to bring fresh perspectives and experience to the company's R&D strategy, further accelerating product development efforts.
See More
Nextech Reduces Stake in Kymera Therapeutics: Analysis
- Transaction Overview: Nextech Invest, Ltd. reduced its stake in Kymera Therapeutics by selling 62,013 shares, valued at approximately $4.19 million, reflecting a cautious management strategy regarding its investment in the company.
- Position Value Change: Despite the sale, the value of Nextech's Kymera position increased by $2.41 million at quarter-end, indicating a positive impact from stock price appreciation on the overall portfolio.
- Asset Allocation Analysis: Kymera now represents 2.1% of Nextech's assets under management, positioning it as a satellite investment compared to the fund's concentrated holdings, highlighting its relatively lower significance in the overall portfolio.
- Market Outlook: Kymera Therapeutics focuses on targeted protein degradation therapies in immunology and oncology; although Nextech trimmed its position, the continued holding indicates confidence in the company's clinical pipeline, suggesting investors should watch for future catalysts.
See More
Nextech Reduces Stake in Kymera Therapeutics
- Transaction Overview: Nextech Invest disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Kymera Therapeutics by 62,013 shares, with an estimated transaction value of $4.19 million, reflecting the company's agile response to market fluctuations.
- Position Value Change: Despite the reduction, the quarter-end value of Kymera's position increased by $2.41 million, indicating a positive impact from stock price appreciation and suggesting Nextech's long-term confidence in the stock.
- Holding Proportion Adjustment: Following this transaction, Nextech's stake in Kymera now represents 2.1% of its assets under management, moving it outside the top five holdings, which highlights the fund's concentrated investment strategy and risk management approach.
- Market Performance Analysis: As of February 17, 2026, Kymera's stock price stood at $84.84, reflecting a 128.5% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its strong position in the biotechnology sector.
See More
Analysis of KYMR Options Trading Dynamics
- Options Selling Risks: Selling puts on KYMR does not provide investors with the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, and unless KYMR's shares decline by 31.3%, the only benefit is a 15.1% annualized return from the premium.
- Cost Basis Analysis: If the contract is exercised, the seller's cost basis would be $52.80 per share after deducting the $7.20 option fee, indicating a mismatch between risk and reward when selling puts at the current market price.
- Volatility Assessment: With a trailing twelve-month volatility of 74% for KYMR, this metric, combined with fundamental analysis, can assist investors in determining whether selling the December put at a $60 strike price is worthwhile, especially given the current stock price of $87.93.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Company Announcement: Kymera Therapeutics plans to sell 200,000 shares of its common stock on March 2.
Market Value: The total market value of the shares being sold is approximately $18.27 million.
See More
Piper Sandler Raises Kymera Price Target to $140 on Strong Clinical Data
- Analyst Rating Upgrade: Piper Sandler raised Kymera Therapeutics' price target from $125 to $140, reflecting strong confidence in its oral protein degraders, which is expected to drive the company's stock price higher.
- Clinical Data Support: Early clinical data indicates that Kymera's STAT6 degrader program can achieve biologic-like pathway suppression in a convenient and scalable oral formulation, further solidifying its position as a category leader.
- Market Competitive Advantage: Piper believes that Kymera's first-mover advantage in immunology degraders and oral differentiation compared to biologics provide an attractive risk-reward profile in the current market environment.
- Optimistic Investment Outlook: With expanding clinical evidence, Piper Sandler maintains an optimistic view on Kymera's future performance, believing it has significant growth potential in the emerging oral atopic dermatitis market.
See More
Kymera Therapeutics Highlights Q4 2025 Earnings Call
- Significant R&D Progress: Kymera Therapeutics achieved a breakout year in 2025, with CEO Mainolfi highlighting outstanding results from KT-621's clinical trials, expecting to share data by mid-2027, indicating substantial potential in the atopic dermatitis market that could drive market share growth.
- Strong Financial Position: The company ended the year with a cash balance of $1.6 billion, with CFO Jacobs reporting collaboration revenue of $2.9 million in Q4 and R&D expenses of $83.8 million, showcasing a robust financial foundation to support future R&D plans and market expansion.
- New Partnerships Established: Kymera formed a new partnership with Gilead focusing on the CDK2 molecular glue program, while ongoing collaboration with Sanofi continues, which will provide additional revenue streams and technical support, enhancing competitive positioning in the market.
- Strategic Leadership Change: The appointment of Neil Graham as the new Chief Development Officer, who previously led the dupilumab project at Regeneron, is expected to bring fresh perspectives and experience to the company's R&D strategy, further accelerating product development efforts.
See More
